Synthetic Health Data Promises More Access, but GDPR Still Sets the Rules

Biomedical research runs on data, but health records are among the hardest to share safely. That is why synthetic data has become such an attractive idea: instead of handing over real patient files, researchers work with machine-generated records that imitate statistical patterns without directly exposing individuals. The appeal is obvious. The hard part is proving that the output is truly non-identifiable, still useful for science, and still compliant with Europe’s privacy framework.

At first glance, synthetic data can look like a clean workaround to the GDPR. In practice, it is better understood as a control strategy. If the synthetic dataset remains personal data, or if the generation model memorized training records, the legal and security picture changes fast. For health systems, that means the problem is not just data access. It is proof, validation, and governance.

Fast Facts

• Health data are special-category data and need stronger protection than ordinary operational records.
• Synthetic data are generated to resemble real data, but similarity alone does not prove privacy.
• Pseudonymized data still fall within GDPR scope in most cases.
• Truly anonymous data can fall outside the GDPR, but anonymity has a strict technical test.
• For research, privacy controls, documentation, and release rules matter as much as the model itself.

Why this matters technically

The central question is whether synthetic health data are actually anonymous or merely less obvious. Under EU data-protection logic, health data receive elevated protection, and research uses rely on safeguards rather than blanket exemptions. That means a synthetic dataset cannot be treated as safe by default. It has to be evaluated for disclosure risk, utility, and the possibility of re-identification through linkage with outside information.

That is where AI creates both opportunity and danger. Generative models can produce plausible records, but they can also absorb patterns too closely from the source material. If that happens, the synthetic output may leak traces of real individuals, especially after repeated releases or when datasets are combined. From a defensive perspective, the sensitive asset is not only the final file. The training corpus, prompts, model parameters, validation logs, and release pipeline can all become part of the risk surface.

For that reason, synthetic data should be tested like any other security control. The right question is not whether it sounds private, but whether privacy and usefulness can be demonstrated together. If a project cannot show that the output is non-identifiable by reasonable means, then the safer assumption is that the GDPR still applies.

Current technical guidance supports a cautious view: synthetic data can reduce disclosure risk, but they do not automatically guarantee anonymity, and they may still require safeguards depending on how they are built, released, and reused.

Conclusion

The bigger lesson is that synthetic data is not a shortcut around privacy law. It is an engineering and governance problem disguised as a data-format debate. In biomedical settings, the winning formula is not just more AI, but better evidence: stronger validation, tighter access control, clearer labeling, and a disciplined test for identifiability. That is how research can move faster without confusing convenience for compliance.

WIKICROOK

• Synthetic data: Artificially generated data designed to mimic patterns in real datasets for analysis or testing.
• GDPR: The EU data-protection law that regulates how personal data are collected, used, and shared.
• Special-category data: Highly sensitive data types under GDPR, including data concerning health, that require extra protection.
• Pseudonymization: Replacing direct identifiers with codes or aliases while the data may still remain personal data.
• Differential privacy: A formal privacy method that limits how much any one person's data can affect an analysis result.